OPKO Health (OPK) Financials

$1.38 +0.04 (+2.59%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$1.39 +0.00 (+0.36%)

As of 05/2/2025 07:59 PM Eastern

Annual Income Statements for OPKO Health

This table shows OPKO Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-172	-30	-48	-305	-153	-315	31	-30	-328	-189	-53
Consolidated Net Income / (Loss)	-175	-31	-48	1,443	-153	-315	31	-30	-328	-189	-53
Net Income / (Loss) Continuing Operations	-175	-31	-48	1,443	-153	-315	31	-30	-328	-189	-53
Total Pre-Tax Income	-171	-138	-97	-272	-177	-305	49	-14	-392	-184	-10
Total Operating Income	-146	-98	-97	-276	-171	-274	58	19	-226	-157	-152
Total Gross Profit	43	256	506	1,129	386	329	541	582	288	318	219
Total Revenue	91	492	1,117	1,749	990	902	1,435	1,775	1,004	863	713
Operating Revenue	91	492	1,117	1,749	990	902	1,435	1,775	1,004	863	713
Total Cost of Revenue	48	235	611	620	605	572	894	1,193	716	545	495
Operating Cost of Revenue	48	235	611	620	605	572	894	1,193	716	545	495
Total Operating Expenses	189	355	603	-344	557	604	483	563	514	475	371
Selling, General & Admin Expense	58	197	407	415	358	343	356	469	373	301	304
Research & Development Expense	96	99	114	126	126	118	75	77	74	90	105
Amortization Expense	11	28	64	71	68	65	56	50	88	86	83
Other Special Charges / (Income)	24	5.05	17	-3.42	-17	-15	-3.99	-33	-20	-1.04	-121
Total Other Income / (Expense), net	-25	-40	-0.27	4.52	-6.07	-31	-9.03	-33	-165	-27	142
Interest Expense	12	8.42	7.43	6.60	12	22	22	19	12	14	47
Interest & Investment Income	0.77	0.26	0.48	0.61	1.24	1.71	0.15	0.03	1.98	3.98	8.43
Other Income / (Expense), net	-14	-31	6.68	11	4.58	-11	13	-14	-155	-18	181
Income Tax Expense	0.02	-114	-56	19	-39	7.06	18	15	-63	4.44	43
Other Gains / (Losses), net	-3.59	-7.11	-7.65	-14	-14	-2.90	-0.48	-0.63	-0.38	-0.11	-0.02
Basic Earnings per Share	($0.41)	($0.06)	($0.09)	($0.55)	($0.27)	($0.53)	$0.05	($0.05)	($0.46)	($0.25)	($0.08)
Weighted Average Basic Shares Outstanding	422.01M	488.07M	550.85M	559.16M	563.14M	595.45M	640.66M	648.08M	719.06M	751.77M	694.02M
Weighted Average Diluted Shares Outstanding	422.01M	488.07M	555.61M	559.16M	563.14M	595.45M	640.66M	681.46M	772.65M	696.99M	671.55M
Weighted Average Basic & Diluted Shares Outstanding	422.01M	488.07M	550.85M	559.16M	563.14M	595.45M	640.66M	681.46M	772.65M	696.99M	671.55M

This table shows OPKO Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-86	-85	-18	-20	-84	-66	-82	-10	25	14
Consolidated Net Income / (Loss)	-86	-85	-18	-20	-84	-66	-82	-10	25	14
Net Income / (Loss) Continuing Operations	-86	-85	-18	-20	-84	-66	-82	-10	25	14
Total Pre-Tax Income	-126	-102	-17	-16	-78	-72	-83	-11	48	35
Total Operating Income	-88	-55	-31	7.03	-64	-69	-71	-62	14	-33
Total Gross Profit	31	56	99	126	48	45	42	52	40	85
Total Revenue	180	185	238	265	179	182	174	182	174	184
Operating Revenue	180	185	238	265	179	182	174	182	174	184
Total Cost of Revenue	148	129	138	139	131	137	132	131	134	99
Operating Cost of Revenue	148	129	138	139	131	137	132	131	134	99
Total Operating Expenses	119	111	130	119	112	114	114	113	26	118
Selling, General & Admin Expense	80	74	76	80	72	73	70	69	98	67
Research & Development Expense	19	20	33	18	19	19	22	24	29	30
Amortization Expense	21	22	21	22	22	21	21	20	20	20
Other Special Charges / (Income)	-0.75	-3.82	0.14	-0.03	-1.13	-0.01	0.00	0.00	0.00	-121
Total Other Income / (Expense), net	-39	-47	14	-23	-14	-3.45	-12	51	34	68
Interest Expense	3.02	3.30	3.39	3.28	3.38	3.45	7.69	8.18	17	14
Interest & Investment Income	0.67	1.14	1.03	1.08	0.97	0.91	0.81	0.39	2.93	4.29
Other Income / (Expense), net	-36	-45	16	-21	-12	-0.90	-4.84	59	49	78
Income Tax Expense	-40	-17	1.23	3.15	6.08	-6.02	-1.35	-0.28	24	21
Other Gains / (Losses), net	-0.04	-0.02	-0.04	-0.04	-0.02	-0.01	-0.00	-0.00	-0.00	-0.01
Basic Earnings per Share	($0.11)	($0.13)	($0.02)	($0.03)	($0.11)	($0.09)	($0.12)	($0.01)	$0.04	$0.01
Weighted Average Basic Shares Outstanding	750.40M	719.06M	751.51M	751.73M	751.53M	751.77M	706.88M	697.21M	694.62M	694.02M
Weighted Average Diluted Shares Outstanding	772.69M	772.65M	772.65M	773.06M	751.53M	696.99M	696.99M	697.38M	998.36M	671.55M
Weighted Average Basic & Diluted Shares Outstanding	772.69M	772.65M	772.65M	773.06M	773.06M	696.99M	696.99M	697.38M	682.48M	671.55M

This table details how cash moves in and out of OPKO Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-89	97	-25	-77	4.97	-11	-13	62	18	-57	350
Net Cash From Operating Activities	-90	164	32	-92	-109	-173	39	38	-95	-28	-183
Net Cash From Continuing Operating Activities	-90	164	32	-92	-109	-173	39	38	-95	-28	-183
Net Income / (Loss) Continuing Operations	-175	-31	-48	-305	-153	-315	31	-30	-328	-189	-53
Consolidated Net Income / (Loss)	-175	-31	-48	-305	-153	-315	31	-30	-328	-189	-53
Depreciation Expense	15	42	97	102	97	94	85	79	109	105	98
Amortization Expense	2.01	1.21	0.24	0.22	0.19	1.00	0.85	0.79	1.16	1.22	1.97
Non-Cash Adjustments To Reconcile Net Income	45	66	1.61	-9.30	57	58	0.07	-13	159	32	-273
Changes in Operating Assets and Liabilities, net	22	86	-18	120	-110	-9.96	-77	1.54	-35	22	43
Net Cash From Investing Activities	-5.68	-99	-21	-47	-26	-13	-18	36	91	-18	352
Net Cash From Continuing Investing Activities	-5.68	-99	-21	-47	-26	-13	-18	36	91	-18	352
Purchase of Property, Plant & Equipment	-4.73	-11	-19	-47	-28	-13	-34	-32	-25	-16	-25
Acquisitions	-1.68	-84	-5.00	-	-	0.00	0.00	-4.00	-1.76	0.00	0.00
Purchase of Investments	-0.59	-4.38	-30	-9.63	-1.00	-1.20	0.00	-2.00	0.00	-5.00	0.00
Sale of Property, Plant & Equipment	0.00	0.00	1.40	7.27	1.22	0.67	0.25	66	1.95	2.71	0.24
Divestitures	-	-	16	-	-	-	-	-	0.00	0.00	210
Sale and/or Maturity of Investments	0.00	0.00	16	2.21	1.52	0.00	15	8.08	115	0.36	167
Net Cash From Financing Activities	7.26	33	-35	61	141	175	-35	-10	23	-11	184
Net Cash From Continuing Financing Activities	7.26	33	-35	61	141	175	-35	-10	23	-11	184
Repayment of Debt	-28	-254	-66	-34	-35	-396	-1,144	-1,696	-1,036	-683	-665
Repurchase of Common Equity	-	-	-	-	-	-	-	-	0.00	0.00	-90
Issuance of Debt	26	261	22	92	82	495	1,108	1,685	1,060	672	939
Other Financing Activities, net	-6.44	-	-	2.13	1.17	-0.00	0.76	1.08	-0.77	-0.27	-0.21
Effect of Exchange Rate Changes	-0.10	-1.12	-1.01	0.47	-	-0.48	0.69	-1.44	-0.34	0.39	-3.16
Cash Interest Paid	6.28	4.57	2.89	1.31	2.08	12	11	8.52	7.42	8.14	21
Cash Income Taxes Paid	0.95	4.88	-27	5.42	-1.41	2.67	-0.90	5.97	8.04	3.71	10

This table details how cash moves in and out of OPKO Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-30	-28	-42	-2.72	31	-43	-20	-35	379	26
Net Cash From Operating Activities	-32	-32	-23	-0.37	33	-38	-36	-26	-77	-44
Net Cash From Continuing Operating Activities	-32	-32	-23	-0.37	33	-38	-36	-26	-77	-44
Net Income / (Loss) Continuing Operations	-86	-85	-18	-20	-84	-66	-82	-10	25	14
Consolidated Net Income / (Loss)	-86	-85	-18	-20	-84	-66	-82	-10	25	14
Depreciation Expense	26	26	26	27	26	26	26	24	24	24
Amortization Expense	0.29	0.30	0.30	0.30	0.31	0.31	0.52	0.43	0.38	0.65
Non-Cash Adjustments To Reconcile Net Income	40	43	-4.21	18	12	6.80	6.94	-50	-120	-111
Changes in Operating Assets and Liabilities, net	-13	-16	-27	-26	79	-4.91	13	8.81	-6.33	28
Net Cash From Investing Activities	-4.68	-7.87	-7.72	-5.49	-3.57	-1.42	-4.40	-7.16	248	116
Net Cash From Continuing Investing Activities	-4.68	-7.87	-7.72	-5.49	-3.57	-1.42	-4.40	-7.16	248	116
Purchase of Property, Plant & Equipment	-7.61	-6.34	-3.04	-6.01	-4.20	-3.02	-4.44	-7.22	-7.94	-5.41
Purchase of Investments	-	-	-5.00	-	-	-	0.00	-	-1.45	1.45
Sale of Property, Plant & Equipment	0.63	0.45	-	-	-	1.60	-	-	-	0.07
Sale and/or Maturity of Investments	-	115	0.32	0.52	-0.48	-	0.05	0.06	47	120
Net Cash From Financing Activities	8.44	10	-13	3.46	2.11	-3.75	21	-2.12	206	-40
Net Cash From Continuing Financing Activities	8.44	10	-13	3.46	2.11	-3.75	21	-2.12	206	-40
Repayment of Debt	-200	-156	-178	-173	-171	-160	-323	-156	-151	-35
Repurchase of Common Equity	-	-	0.00	-	-	-	-50	-	-24	-16
Issuance of Debt	209	166	165	177	173	156	394	154	381	11
Effect of Exchange Rate Changes	-1.15	1.70	1.12	-0.33	-1.13	0.72	-0.89	0.65	2.64	-5.56
Cash Interest Paid	3.47	0.40	3.83	0.37	6.54	-2.61	3.13	0.39	9.47	7.90
Cash Income Taxes Paid	-0.18	3.57	0.48	0.21	-1.51	4.54	1.06	0.51	2.23	6.21

This table presents OPKO Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	-	2,799	2,767	2,590	2,451	2,309	2,473	2,400	2,167	2,012	2,200
Total Current Assets	-	454	484	349	318	324	523	823	395	309	662
Cash & Equivalents	-	194	169	91	96	85	72	135	153	-	432
Accounts Receivable	-	194	220	166	144	135	286	260	127	123	118
Inventories, net	-	40	47	49	42	53	132	87	74	66	57
Prepaid Expenses	-	27	47	43	35	51	32	27	40	25	55
Plant, Property, & Equipment, net	-	132	123	147	145	0.00	141	80	83	75	70
Total Noncurrent Assets	-	2,213	2,160	2,095	1,989	1,985	1,809	1,497	1,690	1,627	1,468
Long-Term Investments	-	35	41	41	31	21	16	11	28	16	55
Goodwill	-	743	705	717	700	672	681	521	596	598	529
Intangible Assets	-	1,430	1,409	1,331	1,250	529	1,065	912	1,019	935	812
Other Noncurrent Operating Assets	-	4.84	5.76	5.62	7.22	764	48	54	47	77	73
Total Liabilities & Shareholders' Equity	-	2,799	2,767	2,590	2,451	2,309	2,473	2,400	2,167	2,012	2,200
Total Liabilities	-	819	675	746	660	695	802	715	606	622	835
Total Current Liabilities	-	252	263	312	288	249	375	330	213	200	193
Short-Term Debt	-	11	12	12	37	9.62	-	15	37	27	15
Accounts Payable	-	73	53	74	47	63	101	82	67	70	47
Accrued Expenses	-	168	198	226	204	165	241	193	98	90	118
Other Current Liabilities	-	-	-	-	-	12	34	12	12	13	13
Total Noncurrent Liabilities	-	567	412	434	371	445	426	385	392	422	642
Long-Term Debt	-	49	44	29	57	211	222	188	210	214	419
Noncurrent Deferred & Payable Income Tax Liabilities	-	226	165	149	115	119	137	148	126	127	141
Other Noncurrent Operating Liabilities	-	292	202	256	199	115	67	48	55	81	82
Total Equity & Noncontrolling Interests	-	1,980	2,092	1,844	1,791	1,615	1,672	1,685	1,562	1,389	1,365
Total Preferred & Common Equity	-	1,980	2,092	1,844	1,791	1,615	1,672	1,685	1,562	1,389	1,365
Total Common Equity	-	1,980	2,092	1,844	1,791	1,615	1,672	1,685	1,562	1,389	1,365
Common Stock	-	2,711	2,851	2,895	3,010	3,150	3,159	3,229	3,430	3,441	3,488
Retained Earnings	-	-705	-730	-1,049	-1,197	-1,511	-1,482	-1,512	-1,823	-2,012	-2,065
Treasury Stock	-	-3.65	-1.91	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79
Accumulated Other Comprehensive Income / (Loss)	-	-23	-27	-0.53	-20	-22	-4.23	-30	-43	-38	-56

This table presents OPKO Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	2,225	2,170	2,159	2,057	1,974	1,980	2,256
Total Current Assets	414	406	434	357	391	358	630
Cash & Equivalents	181	111	108	139	76	41	406
Accounts Receivable	123	121	211	117	111	105	107
Inventories, net	71	75	74	69	59	60	59
Prepaid Expenses	39	99	41	32	25	32	57
Plant, Property, & Equipment, net	0.00	81	79	78	64	67	72
Total Noncurrent Assets	1,811	1,487	1,646	1,621	1,519	1,555	1,554
Long-Term Investments	78	41	28	19	41	101	101
Goodwill	573	597	597	594	531	530	536
Intangible Assets	835	804	782	953	875	854	836
Other Noncurrent Operating Assets	324	45	239	54	72	69	81
Total Liabilities & Shareholders' Equity	2,225	2,170	2,159	2,057	1,974	1,980	2,256
Total Liabilities	596	618	624	612	721	585	853
Total Current Liabilities	267	222	226	201	204	220	212
Short-Term Debt	94	24	29	30	23	22	13
Accounts Payable	50	81	88	67	71	82	63
Accrued Expenses	112	106	99	92	89	95	123
Other Current Liabilities	12	11	11	11	12	12	13
Total Noncurrent Liabilities	328	395	397	412	517	365	641
Long-Term Debt	142	211	212	213	323	176	424
Noncurrent Deferred & Payable Income Tax Liabilities	135	130	133	138	122	119	128
Other Noncurrent Operating Liabilities	52	54	52	60	72	70	89
Total Equity & Noncontrolling Interests	1,629	1,552	1,535	1,445	1,253	1,395	1,403
Total Preferred & Common Equity	1,629	1,552	1,535	1,445	1,253	1,395	1,403
Total Common Equity	1,629	1,552	1,535	1,445	1,253	1,395	1,403
Common Stock	3,427	3,432	3,435	3,438	3,393	3,548	3,524
Retained Earnings	-1,738	-1,841	-1,861	-1,945	-2,094	-2,104	-2,079
Treasury Stock	-	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79
Accumulated Other Comprehensive Income / (Loss)	-58	-38	-37	-46	-45	-47	-40

This table displays calculated financial ratios and metrics derived from OPKO Health's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	615.46%	439.49%	127.25%	56.49%	-43.37%	-8.92%	59.15%	23.64%	-43.42%	-14.01%	-17.41%
EBITDA Growth	-421.55%	39.43%	108.04%	-2,456.56%	57.77%	-175.53%	182.31%	-46.18%	-422.11%	74.86%	288.68%
EBIT Growth	-483.48%	18.62%	30.78%	-195.91%	37.35%	-71.14%	124.71%	-93.15%	-8,002.34%	54.18%	116.41%
NOPAT Growth	-843.30%	32.46%	1.96%	-186.32%	38.07%	-60.08%	119.20%	-64.36%	-1,306.68%	30.60%	3.16%
Net Income Growth	-52.65%	82.00%	-53.87%	3,084.90%	-110.60%	-105.78%	109.71%	-198.55%	-989.49%	42.49%	71.82%
EPS Growth	0.00%	85.37%	-66.67%	0.00%	0.00%	-96.30%	109.43%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	0.00%	281.48%	-80.46%	-387.34%	-18.53%	-58.07%	122.88%	-2.89%	-348.30%	70.38%	-550.74%
Free Cash Flow Firm Growth	209.01%	-339.41%	89.72%	95.62%	-1,384.41%	-29.74%	75.83%	222.52%	-131.59%	90.48%	6,944.94%
Invested Capital Growth	-100.00%	0.00%	6.94%	-9.55%	0.33%	-1.64%	4.41%	-1.95%	-8.08%	-6.67%	-13.55%
Revenue Q/Q Growth	3,554.73%	103.95%	-8.58%	79.11%	-42.16%	0.28%	23.20%	-5.00%	-17.70%	-0.40%	0.24%
EBITDA Q/Q Growth	-159.19%	35.96%	-85.49%	-111.08%	42.98%	-3.00%	3,140.41%	-57.43%	-12.94%	30.25%	727.88%
EBIT Q/Q Growth	-189.96%	18.79%	-90.64%	-49.08%	24.35%	-1.65%	183.79%	-95.90%	-11.23%	14.68%	133.27%
NOPAT Q/Q Growth	-71.44%	19.93%	-213.38%	-43.62%	28.31%	-8.92%	150.54%	-87.16%	3.34%	-9.62%	19.10%
Net Income Q/Q Growth	-28.72%	63.66%	-392.50%	1,261.53%	-110.53%	-13.02%	126.82%	-139.70%	-3.61%	9.03%	60.20%
EPS Q/Q Growth	0.00%	80.00%	-225.00%	0.00%	0.00%	-10.42%	127.78%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	10.37%	521.05%	-44.14%	-50.81%	-7.06%	196.71%	-51.00%	-37.53%	-31.01%	-3.45%
Free Cash Flow Firm Q/Q Growth	1,913.87%	-77.14%	-21.01%	94.45%	-431.19%	-0.90%	59.18%	-52.51%	-142.83%	93.96%	53.85%
Invested Capital Q/Q Growth	-100.00%	-1.81%	-2.31%	-12.42%	-2.10%	-2.92%	0.03%	-1.95%	1.32%	-0.73%	-1.55%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	47.33%	52.16%	45.28%	64.54%	38.94%	36.53%	37.69%	32.77%	28.70%	36.84%	30.64%
EBITDA Margin	-156.45%	-17.57%	0.62%	-9.36%	-6.98%	-21.11%	10.91%	4.75%	-27.05%	-7.91%	18.06%
Operating Margin	-159.97%	-20.03%	-8.64%	-15.81%	-17.29%	-30.38%	4.02%	1.06%	-22.53%	-18.18%	-21.32%
EBIT Margin	-175.03%	-26.40%	-8.04%	-15.21%	-16.83%	-31.62%	4.91%	0.27%	-37.99%	-20.24%	4.02%
Profit (Net Income) Margin	-191.60%	-6.39%	-4.33%	82.54%	-15.45%	-34.92%	2.13%	-1.70%	-32.70%	-21.87%	-7.46%
Tax Burden Percent	102.11%	22.77%	49.95%	-530.83%	86.33%	103.27%	62.83%	214.92%	83.88%	102.47%	513.65%
Interest Burden Percent	107.20%	106.29%	107.74%	102.25%	106.39%	106.95%	69.09%	-290.55%	102.64%	105.45%	-36.13%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	36.19%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-23.00%	-7.61%	-3.61%	-10.49%	-6.83%	-11.00%	2.08%	0.73%	-9.32%	-6.99%	-7.52%
ROIC Less NNEP Spread (ROIC-NNEP)	-1,008.77%	-52.30%	-15.55%	-1,345.46%	46.71%	-312.54%	-2.94%	-38.71%	-234.47%	-87.82%	130.12%
Return on Net Nonoperating Assets (RNNOA)	-17.01%	4.43%	1.23%	83.85%	-1.59%	-7.49%	-0.22%	-2.53%	-10.91%	-5.81%	3.65%
Return on Equity (ROE)	-40.01%	-3.17%	-2.38%	73.36%	-8.42%	-18.49%	1.86%	-1.80%	-20.23%	-12.80%	-3.86%
Cash Return on Invested Capital (CROIC)	177.00%	-207.61%	-10.31%	-0.46%	-7.15%	-9.34%	-2.23%	2.70%	-0.90%	-0.09%	7.01%
Operating Return on Assets (OROA)	-22.93%	-9.28%	-3.23%	-9.93%	-6.61%	-11.98%	2.95%	0.20%	-16.70%	-8.37%	1.36%
Return on Assets (ROA)	-25.10%	-2.25%	-1.74%	53.90%	-6.07%	-13.23%	1.28%	-1.24%	-14.38%	-9.04%	-2.53%
Return on Common Equity (ROCE)	-40.17%	-3.17%	-2.38%	73.36%	-8.42%	-18.49%	1.86%	-1.80%	-20.23%	-12.80%	-3.86%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-1.59%	-2.31%	78.30%	-8.54%	-19.50%	1.83%	-1.79%	-21.03%	-13.59%	-3.90%
Net Operating Profit after Tax (NOPAT)	-102	-69	-68	-194	-120	-192	37	13	-158	-110	-106
NOPAT Margin	-111.98%	-14.02%	-6.05%	-11.07%	-12.10%	-21.27%	2.57%	0.74%	-15.77%	-12.73%	-14.93%
Net Nonoperating Expense Percent (NNEP)	985.77%	44.69%	11.94%	1,334.97%	-53.53%	301.54%	5.02%	39.44%	225.15%	80.83%	-137.64%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-8.76%	-6.74%	-5.91%
Cost of Revenue to Revenue	52.67%	47.84%	54.72%	35.46%	61.06%	63.47%	62.31%	67.23%	71.30%	63.16%	69.36%
SG&A Expenses to Revenue	63.57%	39.98%	36.45%	23.71%	36.19%	38.06%	24.77%	26.42%	37.11%	34.81%	42.66%
R&D to Revenue	104.91%	20.23%	10.19%	7.23%	12.68%	13.07%	5.25%	4.33%	7.36%	10.38%	14.75%
Operating Expenses to Revenue	207.28%	72.19%	53.92%	-19.65%	56.23%	66.91%	33.67%	31.71%	51.23%	55.03%	51.96%
Earnings before Interest and Taxes (EBIT)	-160	-130	-90	-266	-167	-285	70	4.83	-381	-175	29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-143	-86	6.94	-164	-69	-190	157	84	-272	-68	129
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.77	2.48	1.49	0.94	0.61	1.58	1.94	0.62	0.84	0.73
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	2.36	0.00	12.97	0.00	0.00	40.81
Price to Revenue (P/Rev)	47.58	11.14	4.64	1.57	1.70	1.08	1.84	1.85	0.96	1.35	1.41
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	86.53	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.16%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	2.93	2.60	1.51	0.94	0.63	1.54	1.88	0.63	0.85	0.72
Enterprise Value to Revenue (EV/Rev)	47.58	10.80	4.50	1.52	1.67	1.21	1.94	1.88	1.03	1.50	1.33
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	724.60	0.00	0.00	0.00	17.75	39.54	0.00	0.00	7.38
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	39.46	690.79	0.00	0.00	33.16
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	75.50	254.05	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	32.37	156.99	0.00	0.00	0.00	70.44	86.98	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	5.52	0.00	0.00	0.00	0.00	0.00	0.00	69.11	0.00	0.00	9.58
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.03	0.03	0.02	0.05	0.14	0.13	0.12	0.16	0.17	0.32
Long-Term Debt to Equity	0.00	0.02	0.02	0.02	0.03	0.13	0.13	0.11	0.13	0.15	0.31
Financial Leverage	0.02	-0.08	-0.08	-0.06	-0.03	0.02	0.08	0.07	0.05	0.07	0.03
Leverage Ratio	1.59	1.41	1.37	1.36	1.39	1.40	1.46	1.45	1.41	1.42	1.53
Compound Leverage Factor	1.71	1.50	1.47	1.39	1.48	1.49	1.01	-4.22	1.44	1.49	-0.55
Debt to Total Capital	0.00%	2.96%	2.59%	2.18%	5.02%	12.03%	11.72%	10.73%	13.65%	14.82%	24.13%
Short-Term Debt to Total Capital	0.00%	0.56%	0.56%	0.63%	1.98%	0.52%	0.00%	0.78%	2.02%	1.67%	0.83%
Long-Term Debt to Total Capital	0.00%	2.40%	2.04%	1.55%	3.04%	11.51%	11.72%	9.96%	11.63%	13.14%	23.29%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	97.04%	97.41%	97.82%	94.98%	87.97%	88.28%	89.27%	86.35%	85.18%	75.87%
Debt to EBITDA	0.00	-0.70	8.02	-0.25	-1.37	-1.16	1.42	2.40	-0.91	-3.54	3.37
Net Debt to EBITDA	0.00	1.94	-22.21	0.56	0.48	-0.60	0.86	0.68	-0.24	-1.90	-0.41
Long-Term Debt to EBITDA	0.00	-0.57	6.29	-0.18	-0.83	-1.11	1.42	2.23	-0.77	-3.14	3.25
Debt to NOPAT	0.00	-0.88	-0.82	-0.21	-0.79	-1.15	6.03	15.44	-1.56	-2.20	-4.08
Net Debt to NOPAT	0.00	2.44	2.28	0.47	0.28	-0.60	3.64	4.36	-0.41	-1.18	0.49
Long-Term Debt to NOPAT	0.00	-0.71	-0.65	-0.15	-0.48	-1.10	6.03	14.32	-1.33	-1.95	-3.94
Altman Z-Score	0.00	3.77	4.63	1.99	1.04	-0.05	1.89	2.86	-0.24	-0.07	0.03
Noncontrolling Interest Sharing Ratio	-0.39%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	1.80	1.84	1.12	1.10	1.30	1.39	2.49	1.85	1.55	3.43
Quick Ratio	0.00	1.54	1.48	0.82	0.83	0.88	0.95	1.20	1.31	0.62	2.85
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	786	-1,881	-193	-8.46	-126	-163	-39	48	-15	-1.45	99
Operating Cash Flow to CapEx	-1,909.15%	1,512.30%	186.90%	-234.58%	-409.77%	-1,429.35%	118.06%	0.00%	-420.69%	-207.91%	-740.83%
Free Cash Flow to Firm to Interest Expense	64.07	-223.41	-26.01	-1.28	-10.56	-7.57	-1.80	2.56	-1.26	-0.11	2.09
Operating Cash Flow to Interest Expense	-7.37	19.48	4.31	-13.95	-9.18	-8.02	1.80	2.03	-7.90	-2.09	-3.87
Operating Cash Flow Less CapEx to Interest Expense	-7.76	18.19	2.01	-19.90	-11.42	-8.58	0.28	3.82	-9.77	-3.09	-4.39
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.13	0.35	0.40	0.65	0.39	0.38	0.60	0.73	0.44	0.41	0.34
Accounts Receivable Turnover	0.00	0.00	5.40	9.07	6.40	6.48	6.82	6.50	5.19	6.89	5.91
Inventory Turnover	0.00	0.00	14.07	12.84	13.20	11.96	9.63	10.90	8.92	7.80	8.08
Fixed Asset Turnover	0.00	0.00	8.78	12.98	6.80	0.00	0.00	16.11	12.35	10.91	9.80
Accounts Payable Turnover	0.00	0.00	9.71	9.71	9.94	10.42	10.95	13.05	9.61	7.98	8.47
Days Sales Outstanding (DSO)	0.00	0.00	67.64	40.26	57.02	56.36	53.52	56.14	70.32	52.98	61.78
Days Inventory Outstanding (DIO)	0.00	0.00	25.94	28.42	27.66	30.52	37.91	33.47	40.93	46.77	45.20
Days Payable Outstanding (DPO)	0.00	0.00	37.57	37.57	36.73	35.04	33.35	27.98	37.99	45.73	43.08
Cash Conversion Cycle (CCC)	0.00	0.00	56.00	31.11	47.95	51.83	58.08	61.64	73.26	54.02	63.90
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	1,812	1,938	1,753	1,758	1,729	1,806	1,770	1,627	1,519	1,313
Invested Capital Turnover	0.21	0.54	0.60	0.95	0.56	0.52	0.81	0.99	0.59	0.55	0.50
Increase / (Decrease) in Invested Capital	-888	1,812	126	-185	5.73	-29	76	-35	-143	-108	-206
Enterprise Value (EV)	4,337	5,310	5,031	2,650	1,652	1,093	2,781	3,334	1,032	1,297	951
Market Capitalization	4,337	5,477	5,185	2,741	1,685	978	2,647	3,277	966	1,167	1,003
Book Value per Share	$0.00	$3.63	$3.75	$3.30	$3.20	$2.43	$2.49	$2.47	$2.02	$1.80	$2.00
Tangible Book Value per Share	$0.00	($0.36)	($0.04)	($0.37)	($0.28)	$0.62	($0.11)	$0.37	($0.07)	($0.19)	$0.04
Total Capital	0.00	2,040	2,147	1,885	1,886	1,836	1,894	1,888	1,809	1,631	1,800
Total Debt	0.00	60	56	41	95	221	222	203	247	242	434
Total Long-Term Debt	0.00	49	44	29	57	211	222	188	210	214	419
Net Debt	0.00	-168	-154	-91	-33	115	134	57	66	130	-52
Capital Expenditures (CapEx)	4.73	11	17	39	27	12	33	-34	23	14	25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	20	64	-43	-30	-0.91	75	373	64	41	52
Debt-free Net Working Capital (DFNWC)	0.00	214	232	49	67	85	148	508	218	137	484
Net Working Capital (NWC)	0.00	202	220	37	29	75	148	493	181	109	469
Net Nonoperating Expense (NNE)	73	-38	-19	-1,637	33	123	6.24	43	170	79	-53
Net Nonoperating Obligations (NNO)	0.00	-168	-154	-91	-33	115	134	85	66	130	-52
Total Depreciation and Amortization (D&A)	17	43	97	102	98	95	86	80	110	107	100
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	4.07%	5.69%	-2.44%	-2.99%	-0.10%	5.26%	21.02%	6.42%	4.73%	7.30%
Debt-free Net Working Capital to Revenue	0.00%	43.44%	20.79%	2.79%	6.75%	9.37%	10.29%	28.61%	21.67%	15.83%	67.87%
Net Working Capital to Revenue	0.00%	41.11%	19.71%	2.11%	2.97%	8.31%	10.29%	27.78%	18.03%	12.67%	65.76%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.41)	($0.06)	($0.05)	($0.55)	($0.27)	($0.53)	$0.05	($0.05)	($0.46)	($0.25)	($0.08)
Adjusted Weighted Average Basic Shares Outstanding	451.63M	545.70M	558.22M	559.47M	563.14M	669.83M	670.04M	648.08M	719.06M	751.77M	694.02M
Adjusted Diluted Earnings per Share	($0.41)	($0.06)	($0.05)	($0.55)	($0.27)	($0.53)	$0.05	($0.05)	($0.46)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	451.63M	545.70M	558.22M	559.47M	563.14M	669.83M	670.04M	648.08M	719.06M	696.99M	671.55M
Adjusted Basic & Diluted Earnings per Share	($0.41)	($0.06)	($0.05)	($0.55)	$0.00	($0.53)	$0.05	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	422.01M	488.07M	550.85M	559.16M	615.60M	595.45M	640.66M	681.46M	772.65M	696.99M	671.55M
Normalized Net Operating Profit after Tax (NOPAT)	-85	-65	-56	-187	-116	-138	34	-10	-172	-111	-191
Normalized NOPAT Margin	-93.21%	-13.30%	-4.99%	-10.67%	-11.75%	-15.25%	2.39%	-0.57%	-17.16%	-12.81%	-26.85%
Pre Tax Income Margin	-187.63%	-28.06%	-8.66%	-15.55%	-17.90%	-33.81%	3.39%	-0.79%	-38.99%	-21.35%	-1.45%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-13.01	-15.42	-12.10	-40.29	-14.01	-13.25	3.21	0.26	-31.64	-12.94	0.60
NOPAT to Interest Expense	-8.32	-8.19	-9.10	-29.32	-10.08	-8.92	1.68	0.70	-13.14	-8.14	-2.24
EBIT Less CapEx to Interest Expense	-13.40	-16.71	-14.40	-46.23	-16.25	-13.81	1.69	2.05	-33.52	-13.95	0.08
NOPAT Less CapEx to Interest Expense	-8.71	-9.48	-11.40	-35.26	-12.32	-9.48	0.15	2.49	-15.01	-9.14	-2.76
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	1.54%	0.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	1.54%	0.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-169.52%

This table displays calculated financial ratios and metrics derived from OPKO Health's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-53.41%	-53.82%	-27.84%	-14.35%	-0.64%	-1.85%	-26.89%	-31.36%	-2.78%	0.95%
EBITDA Growth	-277.33%	-73.87%	126.37%	122.86%	49.32%	40.42%	-512.78%	72.92%	277.16%	259.49%
EBIT Growth	-446.89%	-62.61%	80.22%	82.91%	38.75%	30.07%	-421.39%	80.39%	182.74%	164.24%
NOPAT Growth	-277.65%	12.39%	57.76%	165.42%	26.66%	-24.92%	-133.61%	-977.86%	116.21%	72.49%
Net Income Growth	-399.56%	-15.53%	67.05%	80.68%	1.88%	22.00%	-348.00%	47.53%	129.47%	121.10%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	127.27%	0.00%
Operating Cash Flow Growth	-196.53%	-460.34%	-14.06%	96.82%	202.71%	-21.11%	-57.05%	-7,142.47%	-332.80%	-15.97%
Free Cash Flow Firm Growth	305.76%	1,256.17%	929.17%	-102.35%	-77.42%	-42.43%	-93.70%	4,812.18%	552.94%	220.04%
Invested Capital Growth	-11.05%	-8.08%	-18.14%	0.64%	-4.75%	-6.67%	-4.77%	-18.27%	-12.82%	-13.55%
Revenue Q/Q Growth	-42.00%	3.11%	28.18%	11.72%	-32.71%	1.85%	-4.52%	4.89%	-4.70%	5.76%
EBITDA Q/Q Growth	-76.62%	24.73%	116.52%	4.07%	-491.55%	11.52%	-14.48%	143.60%	301.16%	-20.34%
EBIT Q/Q Growth	-48.71%	19.35%	85.37%	2.64%	-433.08%	7.92%	-9.10%	96.34%	2,348.69%	-28.51%
NOPAT Q/Q Growth	-717.77%	37.06%	44.65%	122.96%	-1,016.83%	-7.20%	-3.52%	13.71%	116.93%	-281.94%
Net Income Q/Q Growth	15.31%	1.00%	78.57%	-7.52%	-330.11%	21.30%	-23.09%	87.41%	341.53%	-43.64%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-180.87%	1.91%	28.38%	98.39%	9,170.96%	-215.66%	7.12%	25.67%	-191.58%	42.39%
Free Cash Flow Firm Q/Q Growth	-40.44%	-24.29%	185.04%	-101.83%	672.14%	93.00%	-68.83%	1,269.08%	-20.72%	-5.40%
Invested Capital Q/Q Growth	-1.47%	1.32%	-11.48%	13.89%	-6.74%	-0.73%	-9.69%	-2.26%	-0.51%	-1.55%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	17.41%	30.21%	41.78%	47.65%	26.70%	24.58%	24.22%	28.35%	23.11%	46.10%
EBITDA Margin	-54.16%	-39.53%	5.10%	4.75%	-27.62%	-24.00%	-28.77%	11.96%	50.33%	37.91%
Operating Margin	-48.86%	-29.82%	-12.88%	2.65%	-36.06%	-37.96%	-41.15%	-33.85%	8.19%	-18.05%
EBIT Margin	-69.00%	-53.97%	-6.16%	-5.37%	-42.53%	-38.45%	-43.94%	-1.53%	36.20%	24.47%
Profit (Net Income) Margin	-47.90%	-45.99%	-7.69%	-7.40%	-47.30%	-36.55%	-47.12%	-5.66%	14.33%	7.64%
Tax Burden Percent	68.12%	83.41%	107.47%	119.39%	107.78%	91.71%	98.38%	97.36%	51.40%	40.09%
Interest Burden Percent	101.89%	102.16%	116.13%	115.44%	103.18%	103.64%	109.01%	378.68%	77.04%	77.86%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	48.59%	59.87%
Return on Invested Capital (ROIC)	-24.46%	-12.34%	-5.14%	0.98%	-13.96%	-14.58%	-16.38%	-11.39%	2.09%	-3.65%
ROIC Less NNEP Spread (ROIC-NNEP)	-310.19%	-73.97%	13.75%	-297.41%	-139.89%	-33.17%	-863.97%	118.68%	224.05%	67.02%
Return on Net Nonoperating Assets (RNNOA)	-1.57%	-3.44%	0.14%	-1.50%	-2.85%	-2.20%	-2.31%	2.05%	1.25%	1.88%
Return on Equity (ROE)	-26.04%	-15.78%	-5.00%	-0.52%	-16.80%	-16.78%	-18.69%	-9.34%	3.34%	-1.77%
Cash Return on Invested Capital (CROIC)	2.09%	-0.90%	11.88%	-7.77%	-1.53%	-0.09%	-4.96%	7.59%	4.51%	7.01%
Operating Return on Assets (OROA)	-36.27%	-23.73%	-2.51%	-2.06%	-17.23%	-15.89%	-16.96%	-0.53%	11.94%	8.29%
Return on Assets (ROA)	-25.18%	-20.22%	-3.13%	-2.84%	-19.15%	-15.10%	-18.18%	-1.96%	4.73%	2.59%
Return on Common Equity (ROCE)	-26.04%	-15.78%	-5.00%	-0.52%	-16.80%	-16.78%	-18.69%	-9.34%	3.34%	-1.77%
Return on Equity Simple (ROE_SIMPLE)	-19.46%	0.00%	-18.77%	-13.63%	-14.37%	0.00%	-20.15%	-17.42%	-9.53%	0.00%
Net Operating Profit after Tax (NOPAT)	-61	-39	-21	4.92	-45	-48	-50	-43	7.31	-13
NOPAT Margin	-34.20%	-20.87%	-9.01%	1.85%	-25.24%	-26.57%	-28.81%	-23.70%	4.21%	-7.24%
Net Nonoperating Expense Percent (NNEP)	285.73%	61.63%	-18.90%	298.39%	125.94%	18.58%	847.58%	-130.07%	-221.96%	-70.66%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.14%	-	-	-	-2.96%	-	-	-	-0.74%
Cost of Revenue to Revenue	82.59%	69.79%	58.22%	52.35%	73.30%	75.42%	75.78%	71.65%	76.89%	53.90%
SG&A Expenses to Revenue	44.33%	39.93%	31.84%	30.06%	40.45%	40.07%	40.40%	37.78%	56.56%	36.50%
R&D to Revenue	10.45%	10.54%	13.72%	6.84%	10.88%	10.66%	12.63%	13.22%	16.57%	16.57%
Operating Expenses to Revenue	66.27%	60.03%	54.66%	45.01%	62.76%	62.53%	65.37%	62.20%	14.92%	64.15%
Earnings before Interest and Taxes (EBIT)	-124	-100	-15	-14	-76	-70	-76	-2.80	63	45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-97	-73	12	13	-49	-44	-50	22	87	70
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.90	0.62	0.73	1.09	0.86	0.84	0.67	0.62	0.74	0.73
Price to Tangible Book Value (P/TBV)	6.62	0.00	7.48	10.76	0.00	0.00	0.00	78.49	33.35	40.81
Price to Revenue (P/Rev)	1.20	0.96	1.24	1.93	1.43	1.35	1.05	1.22	1.46	1.41
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.89	0.63	0.84	1.09	0.86	0.85	0.78	0.69	0.73	0.72
Enterprise Value to Revenue (EV/Rev)	1.18	1.03	1.33	2.05	1.53	1.50	1.33	1.29	1.36	1.33
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	62.30	7.38
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	33.16
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	40.35	0.00	6.38	0.00	0.00	0.00	0.00	8.20	15.02	9.58
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.14	0.16	0.15	0.16	0.17	0.17	0.28	0.14	0.31	0.32
Long-Term Debt to Equity	0.09	0.13	0.14	0.14	0.15	0.15	0.26	0.13	0.30	0.31
Financial Leverage	0.01	0.05	0.01	0.01	0.02	0.07	0.00	0.02	0.01	0.03
Leverage Ratio	1.37	1.41	1.41	1.39	1.39	1.42	1.48	1.41	1.51	1.53
Compound Leverage Factor	1.39	1.44	1.64	1.61	1.44	1.47	1.61	5.35	1.17	1.19
Debt to Total Capital	12.64%	13.65%	13.19%	13.57%	14.42%	14.82%	21.65%	12.44%	23.76%	24.13%
Short-Term Debt to Total Capital	5.04%	2.02%	1.36%	1.62%	1.78%	1.67%	1.44%	1.40%	0.73%	0.83%
Long-Term Debt to Total Capital	7.60%	11.63%	11.82%	11.95%	12.64%	13.14%	20.21%	11.04%	23.04%	23.29%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	87.36%	86.35%	86.81%	86.43%	85.58%	85.18%	78.35%	87.56%	76.24%	75.87%
Debt to EBITDA	-0.98	-0.91	-1.10	-1.65	-2.49	-3.54	-2.66	-1.64	28.11	3.37
Net Debt to EBITDA	0.10	-0.24	-0.39	-0.72	-0.87	-1.90	-1.76	-0.46	-4.47	-0.41
Long-Term Debt to EBITDA	-0.59	-0.77	-0.99	-1.46	-2.18	-3.14	-2.48	-1.45	27.25	3.25
Debt to NOPAT	-1.44	-1.56	-1.83	-2.07	-2.43	-2.20	-2.50	-1.06	-3.32	-4.08
Net Debt to NOPAT	0.14	-0.41	-0.65	-0.90	-0.85	-1.18	-1.66	-0.30	0.53	0.49
Long-Term Debt to NOPAT	-0.87	-1.33	-1.64	-1.82	-2.13	-1.95	-2.33	-0.94	-3.22	-3.94
Altman Z-Score	0.82	0.19	0.41	0.90	0.28	0.10	-0.40	-0.15	0.07	0.05
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.55	1.85	1.83	1.92	1.78	1.55	1.92	1.63	2.97	3.43
Quick Ratio	1.14	1.31	1.04	1.41	1.28	0.62	0.92	0.66	2.42	2.85
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	138	104	298	-5.45	31	60	19	257	203	192
Operating Cash Flow to CapEx	-461.77%	-537.21%	-745.70%	-6.07%	787.75%	-2,700.56%	-800.50%	-366.29%	-971.14%	-831.63%
Free Cash Flow to Firm to Interest Expense	45.73	31.63	87.79	-1.66	9.21	17.41	2.44	31.37	11.72	13.51
Operating Cash Flow to Interest Expense	-10.68	-9.58	-6.68	-0.11	9.78	-11.09	-4.63	-3.23	-4.44	-3.12
Operating Cash Flow Less CapEx to Interest Expense	-13.00	-11.36	-7.57	-1.95	8.54	-11.50	-5.21	-4.11	-4.90	-3.49
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.53	0.44	0.41	0.38	0.41	0.41	0.39	0.35	0.33	0.34
Accounts Receivable Turnover	6.45	5.19	5.46	4.70	7.21	6.89	6.87	4.53	6.35	5.91
Inventory Turnover	9.54	8.92	6.98	7.07	7.66	7.80	7.99	7.92	8.30	8.08
Fixed Asset Turnover	0.00	12.35	11.21	11.02	0.00	10.91	11.03	9.84	9.46	9.80
Accounts Payable Turnover	12.20	9.61	6.99	7.71	9.22	7.98	7.10	6.23	8.23	8.47
Days Sales Outstanding (DSO)	56.59	70.32	66.84	77.66	50.66	52.98	53.15	80.58	57.47	61.78
Days Inventory Outstanding (DIO)	38.24	40.93	52.27	51.64	47.67	46.77	45.66	46.08	43.97	45.20
Days Payable Outstanding (DPO)	29.91	37.99	52.24	47.34	39.57	45.73	51.38	58.55	44.36	43.08
Cash Conversion Cycle (CCC)	64.92	73.26	66.87	81.96	58.75	54.02	47.43	68.11	57.08	63.90
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,606	1,627	1,440	1,640	1,530	1,519	1,372	1,341	1,334	1,313
Invested Capital Turnover	0.72	0.59	0.57	0.53	0.55	0.55	0.57	0.48	0.50	0.50
Increase / (Decrease) in Invested Capital	-199	-143	-319	10	-76	-108	-69	-300	-196	-206
Enterprise Value (EV)	1,436	1,032	1,212	1,782	1,322	1,297	1,066	927	970	951
Market Capitalization	1,459	966	1,128	1,677	1,237	1,167	836	871	1,039	1,003
Book Value per Share	$2.11	$2.02	$2.01	$1.99	$1.87	$1.80	$1.80	$2.00	$2.01	$2.00
Tangible Book Value per Share	$0.29	($0.07)	$0.20	$0.20	($0.13)	($0.19)	($0.22)	$0.02	$0.04	$0.04
Total Capital	1,865	1,809	1,788	1,776	1,688	1,631	1,599	1,594	1,841	1,800
Total Debt	236	247	236	241	243	242	346	198	437	434
Total Long-Term Debt	142	210	211	212	213	214	323	176	424	419
Net Debt	-23	66	84	105	85	130	229	56	-70	-52
Capital Expenditures (CapEx)	6.98	5.89	3.04	6.01	4.20	1.42	4.44	7.22	7.94	5.34
Debt-free, Cash-free Net Working Capital (DFCFNWC)	60	64	98	128	48	41	134	120	25	52
Debt-free Net Working Capital (DFNWC)	241	218	208	236	187	137	210	161	431	484
Net Working Capital (NWC)	147	181	184	207	157	109	187	138	418	469
Net Nonoperating Expense (NNE)	25	47	-3.15	25	39	18	32	-33	-18	-27
Net Nonoperating Obligations (NNO)	-23	66	-111	105	85	130	119	-55	-70	-52
Total Depreciation and Amortization (D&A)	27	27	27	27	27	26	26	25	25	25
Debt-free, Cash-free Net Working Capital to Revenue	4.90%	6.42%	10.69%	14.74%	5.56%	4.73%	16.80%	16.77%	3.51%	7.30%
Debt-free Net Working Capital to Revenue	19.72%	21.67%	22.83%	27.19%	21.55%	15.83%	26.26%	22.44%	60.64%	67.87%
Net Working Capital to Revenue	12.02%	18.03%	20.16%	23.88%	18.07%	12.67%	23.38%	19.32%	58.75%	65.76%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.11)	($0.13)	($0.02)	($0.03)	($0.11)	($0.09)	($0.12)	($0.01)	$0.04	$0.01
Adjusted Weighted Average Basic Shares Outstanding	750.40M	719.06M	751.51M	751.73M	751.53M	751.77M	706.88M	697.21M	694.62M	694.02M
Adjusted Diluted Earnings per Share	($0.11)	$0.00	($0.02)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.03	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	750.40M	772.65M	751.51M	773.06M	773.06M	696.99M	696.99M	697.38M	998.36M	671.55M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	772.69M	772.65M	772.65M	773.06M	773.06M	696.99M	696.99M	697.38M	682.48M	671.55M
Normalized Net Operating Profit after Tax (NOPAT)	-62	-41	-21	4.89	-46	-48	-50	-43	7.31	-108
Normalized NOPAT Margin	-34.49%	-22.32%	-8.97%	1.84%	-25.69%	-26.57%	-28.81%	-23.70%	4.21%	-58.94%
Pre Tax Income Margin	-70.31%	-55.13%	-7.15%	-6.20%	-43.89%	-39.85%	-47.89%	-5.81%	27.89%	19.05%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-41.11	-30.29	-4.32	-4.35	-22.45	-20.25	-9.93	-0.34	3.62	3.16
NOPAT to Interest Expense	-20.38	-11.72	-6.32	1.50	-13.32	-13.99	-6.51	-5.28	0.42	-0.93
EBIT Less CapEx to Interest Expense	-43.42	-32.07	-5.21	-6.18	-23.69	-20.66	-10.51	-1.22	3.16	2.78
NOPAT Less CapEx to Interest Expense	-22.69	-13.50	-7.21	-0.33	-14.57	-14.40	-7.09	-6.16	-0.04	-1.31
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-169.52%

Frequently Asked Questions About OPKO Health's Financials

When does OPKO Health's financial year end?

According to the most recent income statement we have on file, OPKO Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has OPKO Health's net income changed over the last 10 years?

OPKO Health's net income appears to be on a downward trend, with a most recent value of -$53.22 million in 2024, falling from -$174.64 million in 2014. The previous period was -$188.86 million in 2023. See OPKO Health's forecast for analyst expectations on what’s next for the company.

What is OPKO Health's operating income?

OPKO Health's total operating income in 2024 was -$152.07 million, based on the following breakdown:

Total Gross Profit: $218.51 million
Total Operating Expenses: $370.58 million

How has OPKO Health revenue changed over the last 10 years?

Over the last 10 years, OPKO Health's total revenue changed from $91.15 million in 2014 to $713.14 million in 2024, a change of 682.4%.

How much debt does OPKO Health have?

OPKO Health's total liabilities were at $834.76 million at the end of 2024, a 34.1% increase from 2023, and a 83,476,400,000.0% increase since 2014.

How much cash does OPKO Health have?

In the past 10 years, OPKO Health's cash and equivalents has ranged from $0.00 in 2014 to $431.94 million in 2024, and is currently $431.94 million as of their latest financial filing in 2024.

How has OPKO Health's book value per share changed over the last 10 years?

Over the last 10 years, OPKO Health's book value per share changed from 0.00 in 2014 to 2.00 in 2024, a change of 200.1%.

Related Companies

This page (NASDAQ:OPK) was last updated on 5/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OPKO Health (OPK) Financials

Frequently Asked Questions About OPKO Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OPKO Health (OPK) Financials

Annual Income Statements for OPKO Health

Quarterly Income Statements for OPKO Health

Annual Cash Flow Statements for OPKO Health

Quarterly Cash Flow Statements for OPKO Health

Annual Balance Sheets for OPKO Health

Quarterly Balance Sheets for OPKO Health

Annual Metrics and Ratios for OPKO Health

Quarterly Metrics and Ratios for OPKO Health

Frequently Asked Questions About OPKO Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools